Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 31.80
+0.20 (0.63%)
Sep 8, 2026, 1:30 PM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 8.37 billion as of September 8, 2026. Its market cap has decreased by -31.74% in one year.
Market Cap
8.37B
Enterprise Value
9.86B
Revenue
657.56M
Ranking
n/a
PE Ratio
n/a
Stock Price
31.80
ChartMarket Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 8.37B, a decrease of -50.07%. That is a compound annual growth rate of -6.08%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 8, 2026 | 8.37B | -42.51% |
| Dec 31, 2025 | 14.56B | 36.15% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| TCM Biotech International | 10.00B |
| AP Biosciences | 9.27B |
| Polaris Group | 8.90B |
| PharmaEngine | 8.30B |
| Locus Cell | 8.09B |
| TWi Biotechnology | 7.79B |
| Adimmune | 7.40B |
| Acepodia | 7.05B |